Schneiderman Daniel H 4

What Happened

• Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics (KTTA), was granted an option award covering 1,129,323 shares on May 1, 2026. The Form 4 reports the derivative acquisition price as $0.00. This is an equity compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-01 (reported on Form 4 filed 2026-05-05).
• Transaction type/code: Grant/Award (derivative) — 1,129,323 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Filed 2026-05-05 for a 2026-05-01 grant — appears timely.
• Footnote highlights: Award governed by the Issuer’s 2023 Stock Incentive Plan; vests 33% after one year, then in equal quarterly installments over the next two years; full vesting upon a Change in Control; vested/exercisable shares may be exercised up to three years after termination of service except for termination for Cause.

Context

• This is a compensation grant (an option award). The grant itself does not represent an immediate cash purchase or sale of stock — value is realized only if and when options vest and are exercised (and possibly sold). Such grants are common for executives; purchases or insider sales can be more directly informative about personal conviction. Watch for future Form 4s reporting vesting, exercises, or sales related to this award.